1. Introduction {#sec1-nanomaterials-10-00765}
===============

In recent decades, the role of inflammatory processes in the pathophysiology of age-related diseases and in the development of chronic degenerative diseases has gained interest in the scientific community. Inflammation is a complex biological response that starts in response to internal or external stimuli (e.g., metabolic dysfunctions or pathogens) and involves the upregulation of several enzymes and markers in damaged cells, such as reactive oxygen species (ROS) and reactive nitrogen species (RNS). Their accumulation in damaged cells and tissues, if extreme or prolonged, can lead to the development of several types of chronic diseases \[[@B1-nanomaterials-10-00765],[@B2-nanomaterials-10-00765]\].

Additionally, even in the developed countries, the daily life modification has been associated with increased poor nutrition, consumption of poor-quality foods (in essential nutrients), insufficient physical activity and consumption of tobacco and alcohol. This dangerous lifestyle causes an overproduction of oxidants, thus an imbalance of oxidant and antioxidant levels in human tissues and an excessive accumulation of ROS. This condition is called oxidative stress and can damage cells, tissues and organs. It is involved in several age-related chronic diseases, such as cardiovascular, chronic obstructive pulmonary, neurodegenerative diseases and cancer, significantly affecting life expectancy \[[@B3-nanomaterials-10-00765]\].

Phytochemicals are being investigated as a natural alternative to treat skin conditions associated with inflammation and oxidative stress (e.g., dermatitis, psoriasis, or melanoma), due to their ability to counteract ROS and RNS. According to several studies, the topical administration of anti-inflammatory and antioxidant compounds of natural origin can ameliorate altered skin conditions and restore skin normal functions \[[@B4-nanomaterials-10-00765],[@B5-nanomaterials-10-00765],[@B6-nanomaterials-10-00765]\].

In this scenario, *Lippia citriodora*, also known as *Aloysia citriodora* or lemon verbena, has shown promising beneficial properties. It has been traditionally used as a beverage to calm fever, stomach-ache or gastrointestinal disorders \[[@B7-nanomaterials-10-00765]\]. Phenolic compounds represent a relevant part of the bioactive compounds of *L. citriodora*, with verbascoside and isoverbascoside being the major components \[[@B8-nanomaterials-10-00765]\]. They were proved to possess strong high antioxidant activity \[[@B9-nanomaterials-10-00765]\]. Flavonoids, such as chrysoeriol and luteolin derivatives, have also been detected in *L. citriodora* \[[@B10-nanomaterials-10-00765]\].

Despite the promising beneficial properties of phenolic compounds, their bioavailability in the skin can be hindered by poor solubility and stability \[[@B11-nanomaterials-10-00765]\]. Several strategies have been proposed to overcome these problems. For instance, liposomes and other innovative vesicular systems have been developed to enhance the skin delivery of phenolic compounds extracted from natural sources \[[@B12-nanomaterials-10-00765],[@B13-nanomaterials-10-00765],[@B14-nanomaterials-10-00765]\]. Previous studies underlined the key role played by glycols and polymers in affecting the ability of lamellar vesicles to carry natural molecules to the target sites \[[@B15-nanomaterials-10-00765]\]. The protective effects of phenolic compounds in phospholipid carriers against ROS has been widely demonstrated in vitro \[[@B16-nanomaterials-10-00765],[@B17-nanomaterials-10-00765]\].

The aim of this work was to improve the bioavailability of *L. citriodora* extract by its incorporation into ad hoc formulated natural-based phospholipid vesicles. The extract was obtained by the ecosustainable microwave-assisted extraction, and the components were identified and quantified by HPLC-ESI-TOF/MS. The extract was incorporated in liposomes, glycerosomes (liposomes modified with glycerol) and propylene glycol-containing vesicles (PG-PEVs). Special attention was devoted to formulating phytoformulations by using natural, biocompatible components. Biopolymer-vesicles were also developed by adding a gelatin obtained from *Thunnus albacares* (a species of tuna). The physico-chemical properties of the vesicles and entrapment efficiency were assessed. The in vitro biocompatibility of the *L. citriodora* loaded in vesicles or in solution was evaluated in primary mouse embryonic fibroblasts (3T3), as well as their ability to protect the cells from oxidative stress.

2. Materials and Methods {#sec2-nanomaterials-10-00765}
========================

2.1. Reagents {#sec2dot1-nanomaterials-10-00765}
-------------

Extraction procedures were performed by using a mixture of Milli-Q water (Millipore Bedford, MA, USA) and ethanol (VWR chemicals, Radnor, PA, USA). Analytical assays were performed by using acetonitrile and formic acid (Fisher chemicals, Waltham, MA, USA and Sigma-Aldrich, Steinheim, Germany, respectively). The calibration curves were built by using available commercial standards of verbascoside, loganic acid, kaempferol-3-glucoside, quercetin and apigenin purchased from Extrasynthese (Genay Cedex, France), Fluka or Sigma Aldrich (Steinheim, Germany). The vesicles were prepared by using soy phosphatidylcholine (Phospholipon^®^ 90G; P90G) purchased from Lipoid GmbH (Ludwigshafen, Germany). Glycerol and propylene glycol were purchased from Galeno (Carmignano, PO, Italy). Biogelatin was obtained from yellowfish tuna skin (*Thunnus albacares*) according to the processes previously described by Sousa et al. (2017). Briefly, a set of sequential treatments were applied (alkalis, mineral acid and organic acid) to prepare the fish skin for the thermal extraction (for 16 h at 45 °C) of the aqueous gelatin solution. Then, gelatin was purified by concentration and diafiltration using 30 kDa MWCO ultrafiltration membranes, and oven dried for 72 h at 50 °C. All steps were optimized in order to reduce, as much as possible, the concentration of reagents, the volume of water utilized and the time of processing \[[@B18-nanomaterials-10-00765]\].

2.2. Extraction and Phenolic Quantification by HPLC-ESI-TOF/MS {#sec2dot2-nanomaterials-10-00765}
--------------------------------------------------------------

*L. citriodora* leaves, purchased from Monteloeder (Alicante, Spain), were milled by an ultra-centrifugal mill ZM200 (Retsch GmbH, Haan, Germany) to get an average particle size of 500 µm. The powder was stored in a dry and dark place until extraction. Microwave-assisted extraction (MAE) was performed in a Multiwave 3000SOLV (Anton Paar, Graz, Austria). An extract rich in polar compounds was obtained using 42% ethanol at 113 °C for 22 min \[[@B17-nanomaterials-10-00765]\]. Analytical assays were carried out by reverse-phase HPLC. The chromatographic separation was performed by using a RRLC 1200 series (Agilent Technologies, Palo Alto, CA, USA) with a Zorbax Eclipse Plus C18 analytical column (150 × 4.6 mm id, 1.8 µm particle diameter. Agilent Technologies, Palo Alto, CA, USA) and a multistep gradient elution with a mobile phase of water: acetonitrile 90:10 (v:v) with 0.1% formic acid (A) and acetonitrile (B) for 35 min.

The HPLC was coupled to a mass spectrometer equipped with an orthogonal electrospray interface (ESI; model G1607 from Agilent Technologies, Palo Alto, CA, USA) operating in negative ionization mode considering a mass range of 50--1000 m/z. An external calibration with sodium formate cluster was done in a quadratic high-precision calibration (HPC) regression mode. Source and transfer parameters were set according to a previously reported method \[[@B8-nanomaterials-10-00765]\].

The data provided by the analytical platform were processed by using DataAnalysis 4.0 software (Bruker Daltonics, Bremen, Germany), which allows the identification and quantification of the polar components of extracts. Hence, the qualitative characterization of each compound was made upon an interpretation of their mass spectra data provided by TOF-MS (m/z calculated and experimental, mSigma and molecular formula) and the information available in the literature \[[@B19-nanomaterials-10-00765]\]. For the quantitative characterization, four different calibration curves were built with verbascoside, loganic acid, quercetin and kaempferol-3-glucoside. The calibration curves were built by plotting the standard concentration as a function of the peak area given by HPLC-ESI-TOF analyses (area standard/area internal standard). Apigenin was used as internal standard (25 µg/mL). In all cases, the linearity of calibration curves was higher than 0.99. Detection and quantification limits, as well as repeatability of the method (intraday and interday precision) was previously reported \[[@B8-nanomaterials-10-00765]\].

The extract was dissolved in water:ethanol (50:50 v:v) to reach a concentration of 5 mg/mL. The concentration of the phytochemicals was calculated by interpolation of the area analyte/area internal standard ratio in the corresponding calibration curve. Iridoid glycosides were quantified using loganic acid calibration curve. According to their structures, luteolin-7-diglucuronide, chrysoeriol-7-diglucuronide, apigenin-7-diglucuronide and acacetin-7-diglucuronide were quantified by using the kaempferol-3-glucoside curve. The amounts of the rest of flavonoids were calculated by using the quercetin calibration curve. Lastly, verbascoside calibration curve was used to quantify the phenylpropanoids group. The results were expressed as mg of analyte per g of *L. citriodora* extract.

2.3. Vesicle Preparation {#sec2dot3-nanomaterials-10-00765}
------------------------

P90G (180 mg/mL) and the extract (50 mg/mL) were dispersed in water to prepare liposomes, and in a blend of glycerol or propylene glycol in water (25% *v*/*v*) to prepare glycerosomes and PG-PEVs, respectively. The composition of the vesicles is reported in [Table 1](#nanomaterials-10-00765-t001){ref-type="table"}. The dispersions were sonicated at an amplitude of 14 micron, 25 cycles, 5 seconds ON and 2 seconds OFF with a Soniprep 150 ultrasonic disintegrator (MSE Crowley, London, UK). After that, the formulations were stored in the dark at 4 °C until use.

2.4. Vesicle Characterization {#sec2dot4-nanomaterials-10-00765}
-----------------------------

The morphology of the vesicles was evaluated by cryogenic-transmission electron microscopy (cryo-TEM). The procedure followed to prepare the samples was previously reported by Manca et al. \[[@B15-nanomaterials-10-00765]\]. Briefly, a thin aqueous film was formed by placing a drop of each sample on a glow-discharged drilled carbon grid, and blotting the grid on filter paper. The film was then vitrified by plunging the grid (maintained at 100% humidity and room temperature) into ethane at melting point, by using a Vitrobot (FEI Company, Eindhoven, The Netherlands). After that, the vitreous film was transferred to a Tecnai F20 TEM (FEI Company, Eindhoven, The Netherlands) and the samples were observed in a low-dose mode. Image acquisition was made at 200 kV at a temperature between −170 and −175 °C with a CCD Eagle camera (FEI Company, Eindhoven, The Netherlands).

The physicochemical properties of the vesicles were checked by using a Zetasizer nano-ZS (Malvern Instruments, Worcestershire, UK). The average diameter (D) and polydispersity index (PDI) were determined by photon correlation spectroscopy, and the zeta potential by electrophoretic light scattering \[[@B20-nanomaterials-10-00765]\]. Prior to each analysis, samples were diluted (1:100) by using the appropriate mixture (water, water-glycerol or water-propylene glycol).

In order to evaluate the entrapment efficiency, the extract-loaded vesicles were purified from the non-entrapped bioactives by dialysis. Briefly, 1 mL of each formulation was loaded into dialysis tubes (Spectra/Por^®^ membranes, 12--14 kDa MW cut-off, Spectrum Laboratories Inc., Rancho Dominguez, CA, USA) and dialyzed against water for 2 h at 25 °C (refreshing water after 1 h). Both non-dialyzed and dialyzed samples were assayed with the DPPH (2,2-diphenyl-1-picrylhydrazyl) test. Each sample was diluted (1:50) with methanol and 60 µL of the dilution was added to a DPPH methanolic solution (40 μg/mL; 1940 µL). The samples were stored in the dark at room temperature for 30 min. After that, absorbance was measured at 517 nm. The antioxidant activity (AA) results were expressed as mg of gallic acid equivalents/mg of extract in the formulation. All experiments were performed in triplicate. The entrapment efficiency (EE) was calculated as the percentage of the antioxidant activity (AA) of dialyzed samples versus non-dialyzed ones, according to the following equation: $$EE\% = \frac{AA~Dialyzed}{AA~Non - dialyzed} \times 100$$

2.5. In Vitro Biocompatibility Assessment of the Formulations {#sec2dot5-nanomaterials-10-00765}
-------------------------------------------------------------

To evaluate the biocompatibility of the vesicle formulations, primary mouse embryonic fibroblasts (3T3, ATCC collection, USA) were grown as a monolayer in 75 cm^2^ flasks, at 37 °C, 100% humidity and 5% CO~2~, using Dulbecco's modified eagle's medium (DMEM) with high glucose, 10% of bovine serum, penicillin-streptomycin and fungizone. 96-well plates were used to seed fibroblasts (2.5 × 10^6^ cells/well), which were incubated for 24 h. After that, the cells were treated for 48 h with the extract incorporated in the vesicles or dissolved in water, properly diluted to reach the required concentrations (50, 5, 0.5 and 0.05 µg/mL). The cells were washed with fresh medium and their viability was evaluated by the MTT (3(4,5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) colorimetric assay. One hundred microliters of the MTT reagent (0.5 mg/mL in PBS, final concentration) were added to each well. After 3 h, the formazan crystals produced in living cells, were dissolved in 100 µL of DMSO and the absorbance was read at 570 nm with a microplate reader (Synergy 4, Reader BioTek Instruments, AHSI S.P.A, Bernareggio, Italy). The experiments were made in accordance with the protocols described in ISO 10,993 \[[@B21-nanomaterials-10-00765]\] and at least in triplicate, and the results were expressed as a percentage of cell viability in comparison with untreated cells (100% viability).

2.6. Protective Efficacy of the Formulations against Cells Stressed with Hydrogen Peroxide {#sec2dot6-nanomaterials-10-00765}
------------------------------------------------------------------------------------------

The ability of *L. citriodora* extract in solution or loaded in the vesicles to protect fibroblasts from oxidative stress was evaluated. The cells were seeded in a 96-well plate and incubated at 37 °C, 100% humidity and 5% CO~2~ for 24 h. The cells were exposed to hydrogen peroxide (1:50000 dilution) for 4 h and treated with the different formulations (50 and 5 µg/mL) or an aqueous solution of the extract. At the end of the experiment, the cells were washed with PBS, and the MTT assay was performed to evaluate the protective effect of the samples. Untreated cells (100% viability) were used as a negative control, whereas hydrogen peroxide-treated cells were used as a positive control.

2.7. Statistical Analysis of Data {#sec2dot7-nanomaterials-10-00765}
---------------------------------

The results were expressed as mean values ± standard deviations. Statistically significant differences were determined by using variance analysis, and the Student's *t*-test. The minimum level of significance chosen was *p* \< 0.05.

3. Results {#sec3-nanomaterials-10-00765}
==========

3.1. Characterization of L. citriodora Extract {#sec3dot1-nanomaterials-10-00765}
----------------------------------------------

The extract from *L. citriodora* leaves was obtained by environmentally friendly microwave-assisted extraction, tuning the operating conditions to achieve the maximum concentration of polar compounds. The bioactive components of the extract were quantified by HPLC-ESI-TOF-MS ([Figure 1](#nanomaterials-10-00765-f001){ref-type="fig"}). [Table 2](#nanomaterials-10-00765-t002){ref-type="table"} shows a summary of the calculated parameters: retention time (min), m/z, molecular formula (M-H), chemical group, proposed name and amount expressed as mg of analyte per g of extract. The extract was found to be a complex mixture of polar compounds: 49 compounds were detected. Phenylpropanoids were the most abundant chemical group with 18 compounds accounting for 266 mg/g of extract. Among phenylpropanoids, verbascoside was the most representative (187 mg/g of extract), followed by isoverbascoside (57.3 mg/g of extract). Other phenylpropanoids, such as leucoseptoside A, verbascoside derivatives or cistanoside F, were found in relevant amounts. Oxoverbascoside, lariciresinol glucopyranoside, verbascoside A, lipedoside A I or osmanthisude were also detected, but in lower amounts. Flavonoids were the second major group found in the extract (18.2 mg/g of extract). Seven compounds were identified, with three aglycones and four glucuronic derivatives. Chrysoeriol-7-dilucuronide was the most abundant flavonoid (8.1 mg/g of extract). Luteolin-7-diglucuronide and apigenin-7-diglucuronide were detected in high amounts (3.81 and 2.6 mg/g of extract, respectively). Dimethyl quercetin was the most representative aglycone with 2.8 mg/g of extract, whereas methyl quercetin and dimethyl kaempferol were detected in lower amounts. Moreover, iridoid glycosides were a heterogeneous group with 13 compounds accounting for 12.9 mg/g of extract, with theveside, gardoside and ixoside being the most abundant compounds (\> 1 mg/g of extract). The total polar content of the extract was almost 300 mg/g of extract.

Considering other studies on the recovery of phytochemicals from *L. citriodora* by pressurized liquid extraction (PLE), MAE was found to be an advanced extraction technology that allowed the recovery of a greater number of compounds from this botanical source. More specifically, three new compounds were found in our extract, as compared to the extracts obtained by PLE or conventional solid--liquid extraction \[[@B8-nanomaterials-10-00765],[@B17-nanomaterials-10-00765]\].

Taking into account the findings of previous research, some phytochemicals in *L. citriodora* are responsible for the antioxidant effects of its extract, suggesting its use for the treatment of skin disorders associated with oxidative stress and inflammation \[[@B22-nanomaterials-10-00765],[@B23-nanomaterials-10-00765],[@B24-nanomaterials-10-00765]\].

3.2. Preparation and Characterization of Vesicles {#sec3dot2-nanomaterials-10-00765}
-------------------------------------------------

The extract was incorporated in glycerosomes and PG-PEVs aiming at improving the stability of the phytochemicals extracted from *L. citriodora* and promoting their antioxidant efficacy. In order to preserve the green approach in the formulation project, the vesicles were prepared by using a simple preparation method that avoids the use of organic solvents. Only natural components and food-grade solvents were employed. In addition, the stability and carrier performances of the vesicles were improved by adding a biopolymer (biogelatin) extracted from fish by-product of *T. albacares*. *L. citriodora* extract loaded liposomes formulated without water-cosolvents and gelatin were prepared by the same procedure and used as a reference. The composition of the vesicles is reported in [Table 1](#nanomaterials-10-00765-t001){ref-type="table"}.

The assessment of the morphology of the vesicles was achieved by cryo-TEM analyses. Liposomes ([Figure 2](#nanomaterials-10-00765-f002){ref-type="fig"}A) were spherical and mainly unilamellar; bilamellar vesicles were also observed. Glycerosomes and PG-PEVs ([Figure 2](#nanomaterials-10-00765-f002){ref-type="fig"}B,C, respectively) were multilamellar and multicompartment structures, probably due to the presence of glycols \[[@B25-nanomaterials-10-00765]\]. The effect of gelatin on the vesicle morphology was not relevant, as they showed a structure similar to the corresponding vesicles without gelatin (figures not shown).

The results of size, polydispersity index and zeta potential of the vesicles are reported in [Table 3](#nanomaterials-10-00765-t003){ref-type="table"}. Empty vesicles were also prepared, in order to evaluate the effect of the incorporation of the *L. citriodora* extract on the vesicles' assembly. Empty liposomes were around 99 nm, and the loading of the extract led to an increase in mean diameter (151 nm, *p* \< 0.01), which indicates an important contribution of the extract components to vesicle assembly. The addition of glycols to empty vesicles induced a slight increase in the mean diameter of glycerosomes (135 nm, *p* \< 0.05 vs. liposomes) and a strong increase for PG-PEVs (310 nm). The addition of biogelatin caused a further increase in size for biogelatin-glycerosomes (202 nm, *p* \< 0.05 vs. glycerosomes) and a decrease for biogelatin-PG-PEVs (235 nm). Unlike liposomes, the loading of the extract in the vesicles containing glycols caused a reduction in size, except for glycerosomes, which remained unchanged (133 nm, *p* \> 0.05 vs. empty glycerosomes). The effect of the extract was especially evident in PG-PEVs whose size decreased from 310 to 109 nm, becoming the smallest vesicles (*p* \< 0.05 vs. the other glycol-vesicles). This behavior can be ascribed to a positive contribution of propylene glycol to the intercalation and loading of the extract components within the vesicles. As reported in [Table 2](#nanomaterials-10-00765-t002){ref-type="table"}, the extract was mostly composed by phenylpropanoids and flavonoids with glucuronic moieties. These phenolic compounds had good solubility in water. Therefore, their localization within the vesicles might be in the internal polar regions of the bilayers, a fact that can cause the downsizing of the vesicles. The effect of biogelatin on the mean diameter of extract loaded glycol-vesicles was not relevant: it only caused a slight increase in size.

With regard to the polydispersity results, vesicles are considered monodispersed when PDI values approach zero, whereas values close to 1 indicate a heterogeneous size distribution \[[@B26-nanomaterials-10-00765]\]. The PDI values of our formulations displayed that the homogeneity of the vesicles loaded with *L. citriodora* extract was much higher than that of the corresponding empty particles, with the exception of liposomes. Extract-loaded glycerosomes and PG-PEVs were highly monodispersed (PDI \< 0.2), much more than the corresponding empty vesicles (PDI up to 0.65). These results can be related to a possible interaction between glycerol or propylene glycol with the phenolic compounds of the extract, which positively affected the packing of the vesicles resulting in higher homogeneity. Furthermore, the biogelatin added to these formulations (5 mg/mL) could interact with the phospholipid providing, during vesicles' production, a supramolecular structure where the biopolymer was intercalated in the bilayer, contributing to modify the lamellar arrangement and providing better results in terms of size and homogeneity ([Table 3](#nanomaterials-10-00765-t003){ref-type="table"}) \[[@B12-nanomaterials-10-00765]\]. Zeta potential was also measured, as it is predictive of the stability of colloidal dispersions \[[@B26-nanomaterials-10-00765]\]. The results ([Table 3](#nanomaterials-10-00765-t003){ref-type="table"}) showed that the incorporation of the extract modified the surface charge of the vesicles, with zeta potential values around −8 mV, regardless of the vesicle type.

Due to the great number of structurally different phytochemicals contained in the *L. citriodora* extract ([Table 2](#nanomaterials-10-00765-t002){ref-type="table"}), the entrapment efficiency was estimated by evaluating the antioxidant activity of the whole extract in dialyzed and non-dialyzed formulations. Liposomes showed the highest value of entrapment efficiency (89%). The presence of glycerol, propylene glycol or gelatin provided lower entrapment efficiency (65%). These results may be explained by taking into account the high solubility of extract phytochemicals in the solvent used for the purification of the formulations \[[@B1-nanomaterials-10-00765]\].

3.3. In Vitro Assays in Fibroblasts {#sec3dot3-nanomaterials-10-00765}
-----------------------------------

### 3.3.1. Biocompatibility Assay {#sec3dot3dot1-nanomaterials-10-00765}

In order to evaluate the influence of the extract on the viability of skin cells, biocompatibility studies were performed by incubating 3T3 cells for 48 h with each formulation at different concentrations. As can be seen in [Figure 3](#nanomaterials-10-00765-f003){ref-type="fig"}, when the higher concentrations (50 and 5 µg/mL) were used, the viability of the cells treated with the extract solution was lower than that detected in cells treated with the vesicle formulations. At lower concentrations (0.5 and 0.05 µg/mL) of the extract solution, the viability was 100%, which confirmed the biocompatibility of the extract. The incubation with extract-loaded vesicles did not alter the viability of the cells, which was always \>100%, except when liposomes were used at the higher concentration (50 µg/mL). In the case of liposomes and glycerosomes, the viability was concentration-dependent: it increased as the concentration of the extract decreased. A different behavior was observed in cells treated with PG-PEVs: the viability was around 100% at all the concentrations tested. Opposing results were obtained when gelatin-glycol-vesicles were used. In the cells treated with gelatin-glycerosomes, the viability was around 100%, approaching 120% at the higher extract concentration. On the other hand, in the cells treated with PG-PEVs with gelatin, the higher viability (110%) was found at the intermediate concentrations (5 and 0.5 µg/mL). These findings point to the high biocompatibility of the extract-loaded vesicles, which even triggered a proliferative effect as a function of the concentration used. The statistical analysis has been included in [Supplementary Material Table S1](#app1-nanomaterials-10-00765){ref-type="app"}.

### 3.3.2. Antioxidant Assay {#sec3dot3dot2-nanomaterials-10-00765}

Given the promising physico-chemical characteristics of the vesicles (i.e., small size and homogeneity) and their high biocompatibility in skin cells (over 100% of fibroblast viability), further studies were carried out. In particular, the ability of the extract to protect skin cells from oxidative stress induced by hydrogen peroxide was evaluated. The effectiveness against oxidative stress was evaluated using vesicle formulations at 5 µg/mL because this concentration did not cause any toxic effect (viability ≥ 100%). In addition, the highest concentration (50 µg/mL) was used to evaluate if it could give different results. At this concentration, only extract-loaded liposomes caused a low toxicity, but a high extract concentration is expected to neutralize a greater number of the ROS produced by hydrogen peroxide (1:50000).

The exposure of fibroblasts to hydrogen peroxide increases the intracellular ROS concentration causing cell death via apoptosis or necrosis \[[@B27-nanomaterials-10-00765]\]. The results in [Figure 4](#nanomaterials-10-00765-f004){ref-type="fig"} confirmed a marked cell death after exposure to hydrogen peroxide, with an approximate 50% survival. The aqueous solution of the extract at 5 µg/mL was able to counteract the harmful effects of hydrogen peroxide, providing 95% of viability. The extract loaded vesicles provided a great protection against oxidative stress. The viability was always higher than 85%, with liposomes and biogelatin-PG-PEVs being the least effective, and glycerosomes and biogelatin-glycerosomes being the most effective (\> 100% viability). Although fibroblasts are located in the deep strata of the skin, they can be reached and protected by the bioactive compounds of the extract thanks to the enhanced delivery of the vesicles \[[@B1-nanomaterials-10-00765]\]. Overall, all formulations demonstrated a significant potential in protecting skin cells from damages caused by H~2~O~2~. Nevertheless, glycerosomes and biogelatin-glycerosomes displayed the best results in terms of in vitro biocompatibility and antioxidant protective effect, which suggests a better ability to interact with cells and promote the release of the extract bioactives.

4. Conclusions {#sec4-nanomaterials-10-00765}
==============

The performed environmentally friendly microwave-assisted extraction allowed the production of an extract from *L. citriodora* rich in polyphenolic compounds. The obtained extract showed a good protective effect against oxidative stress in skin cells. The total-green approach allowed the development of phospholipid vesicles based on biocompatible components. The vesicle formulations enhanced the ability of the extract to neutralize the ROS produced by hydrogen peroxide in skin cells. Particularly, glycerosomes and biogelatin-glycerosomes showed the highest protective effects. These promising results suggest the use of *L. citriodora* extract-loaded biogelatin-glycerosomes for the production of innovative cosmeceuticals as a green alternative to ameliorate skin disorders.
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![Cryo-TEM micrographs of *L. citriodora* extract loaded in liposomes (**A**), glycerosomes (**B**) and propylene glycol-containing vesicles (PG-PEVs; **C**).](nanomaterials-10-00765-g002){#nanomaterials-10-00765-f002}

![Biocompatibility assay of *L. citriodora* loaded vesicles performed on fibroblasts.](nanomaterials-10-00765-g003){#nanomaterials-10-00765-f003}

![Antioxidant assay of *L. citriodora* loaded vesicles performed on fibroblasts (\*\*\* = *p* value \< 0.001).](nanomaterials-10-00765-g004){#nanomaterials-10-00765-f004}

nanomaterials-10-00765-t001_Table 1

###### 

Composition of the vesicle formulations.

  -------------------------------------------------------------------------------------------------------------------------------------------------
  Formulation                               *L. citriodora* Extract (mg)   P90G (mg)   Gelatine (mg)   H~2~O\   Glycerol (mL)   Propylene Glycol\
                                                                                                       (mL)                     (mL)
  ----------------------------------------- ------------------------------ ----------- --------------- -------- --------------- -------------------
  Empty liposomes                           \-                             180         \-              1        \-              \-

  Empty glycerosomes                        \-                             180         \-              0.75     0.25            \-

  Empty PG-PEVs                             \-                             180         \-              0.75     \-              0.25

  Empty biogelatin-glycerosomes             \-                             180         5               0.75     0.25            \-

  Empty biogelatin-PG-PEVs                  \-                             180         5               0.75     \-              0.25

  *L. citriodora* liposomes                 50                             180         \-              1        \-              \-

  *L. citriodora* glycerosomes              50                             180         \-              0.75     0.25            \-

  *L. citriodora* PG-PEVs                   50                             180         \-              0.75     \-              0.25

  *L. citriodora* biogelatin-glycerosomes   50                             180         5               0.75     0.25            \-

  *L. citriodora* biogelatin-PG-PEVs        50                             180         5               0.75     \-              0.25
  -------------------------------------------------------------------------------------------------------------------------------------------------

nanomaterials-10-00765-t002_Table 2

###### 

Qualitative and quantitative results of *L. citriodora* extract.

  --------------------------------------------------------------------------------------------------------------------------------------------
  Peak     RT (min)   m/z Cal    m/z Exp    Formula\          Proposed Compound                     Chemical Group      Quantification\
                                            (M-H)                                                                       mg Analyte/g Extract
  -------- ---------- ---------- ---------- ----------------- ------------------------------------- ------------------- ----------------------
  **1**    2.8        195.0510   195.0508   C~6~H~11~O~7~     Gluconic acid                         Organic acid        \-

  **2**    3.8        373.1140   373.1131   C~16~H~21~O~10~   Gardoside                             Iridoid glycoside   4.4 ± 0.3

  **3**    3.9        391.1246   391.1241   C~16~H~23~O~11~   Shanzhiside                           Iridoid glycoside   0.24 ± 0.02

  **4**    4.0        387.0933   387.0933   C~16~H~19~O~11~   Ixoside                               Iridoid glycoside   1.78 ± 0.03

  **5**    4.2        461.1664   461.1670   C~20~H~29~O~12~   Verbasoside                           Phenylpropanoid     3.56 ± 0.02

  **6**    4.8        487.1457   487.1443   C~21~H~27~O~13~   Cistanoside F                         Phenylpropanoid     1.72 ± 0.06

  **7**    5.2        203.0925   203.0907   C~9~H~15~O~5~     UK 1                                  \-                  \-

  **8**    5.3        475.1398   475.1435   C~20~H~27~O~13~   Primeverin                            Other               \-

  **9**    5.8        285.0616   285.0591   C~12~H~13~O~8~    Pyrocatechol Glucuronide              Other               \-

  **10**   5.9        389.1089   389.1077   C~16~H~21~O~11~   Theveside                             Iridoid glycoside   4.8 ± 0.1

  **11**   7.4        449.1301   449.1301   C~18~H~25~O~13~   Myxopyroside                          Iridoid glycoside   0.271 ± 0.005

  **12**   8.5        489.1614   489.1618   C~21~H~29~O~13~   Teucardoside                          Iridoid glycoside   0.108 ± 0.002

  **13**   8.7        387.1661   387.1640   C~18~H~27~O~9~    Tuberonic acid glucoside              Other               \-

  **14**   9.0        433.2079   433.2077   C~20~H~33~O~10~   UK 2                                  \-                  \-

  **15**   9.5        641.2087   641.2028   C~29~H~37~O~16~   β-Hydroxyverbascoside derivative      Phenylpropanoid     0.28 ± 0.03

  **16**   10.0       641.2087   641.2065   C~29~H~37~O~16~   β-Hydroxyisoverbascoside derivative   Phenylpropanoid     0.65 ± 0.05

  **17**   10.6       639.1931   639.1912   C~29~H~35~O~16~   β-Hydroxyverbascoside                 Phenylpropanoid     1.85 ± 0.09

  **18**   10.6       637.1046   637.1048   C~27~H~25~O~18~   Luteolin-7-diglucoronide              Flavonoid           3.81 ± 0.01

  **19**   11.0       639.1931   639.1923   C~29~H~35~O~16~   β-Hydroxyisoverbascoside              Phenylpropanoid     1.93 ± 0.04

  **20**   11.6       553.1563   553.1572   C~25~H~29~O~14~   Lippioside II                         Iridoid glycoside   0.21 ± 0.03

  **21**   13.1       639.1872   639.1879   C~36~H~31~O~11~   UK 3                                  \-                  \-

  **22**   13.8       637.1774   637.1811   C~29~H~33~O~16~   Oxoverbascoside                       Phenylpropanoid     0.043 ± 0.003

  **23**   14.3       621.1097   621.1115   C~27~H~25~O~17~   Apigenin-7-diglucoronide              Flavonoid           0.39 ± 0.01

  **24**   14.6       535.1457   535.1442   C~25~H~27~O~13~   Lippioside I derivative               Iridoid glycoside   0.11 ± 0.01

  **25**   15.1       537.1614   537.1595   C~25~H~29~O~13~   Lippioside I                          Iridoid glycoside   0.35 ± 0.01

  **26**   15.6       653.2087   653.2058   C~30~H~37~O~16~   Campneoside I                         Phenylpropanoid     NQ

  **27**   16.1       651.1355   651.1212   C~28~H~27~O~18~   Chrysoeriol-7-diglucuronide           Flavonoid           8.1 ± 0.7

  **28**   16.4       623.1981   623.1998   C~29~H~35~O~15~   Verbascoside                          Phenylpropanoid     187 ± 2

  **29**   17.9       521.2028   521.2031   C~26~H~33~O~11~   Lariciresinol glucopyranoside         Phenylpropanoid     1.08 ± 0.04

  **30**   18.7       667.2244   667.2230   C~31~H~39~O~16~   Verbascoside A                        Phenylpropanoid     0.62 ± 0.01

  **31**   18.9       623.1981   623.1991   C~29~H~35~O~15~   Isoverbascoside                       Phenylpropanoid     57.3 ± 0.8

  **32**   19.4       623.1981   623.1973   C~29~H~35~O~15~   Forsythoside A                        Phenylpropanoid     0.39 ± 0.03

  **33**   19.4       549.1614   549.1645   C~26~H~29~O~13~   Lippianoside B                        Iridoid glycoside   0.18 ± 0.06

  **34**   19.8       521.1664   521.1673   C~25~H~29~O~12~   Hydroxycampsiside                     Iridoid glycoside   0.16 ± 0.02

  **35**   20.2       607.2032   607.2057   C~29~H~35~O~14~   Lipedoside A I                        Phenylpropanoid     0.13 ± 0.03

  **36**   20.7       551.1770   551.1774   C~26~H~31~O~13~   Durantoside I                         Iridoid glycoside   0.32 ± 0.01

  **37**   21.3       637.2138   637.2150   C~30~H~37~O~15~   Leucoseptoside A                      Phenylpropanoid     4.07 ± 0.01

  **38**   24.2       635.1254   635.1277   C~28~H~27~O~17~   Acacetin-7-diglucoronide              Flavonoid           2.6 ± 0.1

  **39**   25.2       551.2498   551.2539   C~28~H~39~O~11~   UK 4                                  \-                  \-

  **40**   26.0       467.2134   467.2146   C~20~H~35~O~12~   UK 5                                  \-                  \-

  **41**   26.3       549.1614   549.1640   C~26~H~29~O~13~   UK 6                                  \-                  \-

  **42**   27.2       651.2294   651.2303   C~31~H~39~O~15~   Martynoside or isomer                 Phenylpropanoid     3.0 ± 0.1

  **43**   29.6       651.2294   651.2293   C~31~H~39~O~15~   Martynoside or isomer                 Phenylpropanoid     0.69 ± 0.02

  **44**   30.9       591.2083   591.2163   C~29~H~35~O~13~   Osmanthuside B                        Phenylpropanoid     1.33 ± 0.03

  **45**   31.4       569.2240   569.2243   C~27~H~37~O~13~   Manuleoside H                         Iridoid glycoside   NQ

  **46**   32.1       315.0510   315.0507   C~16~H~11~O~7~    Methyl quercetin                      Flavonoid           NQ

  **47**   33.8       327.2177   327.2182   C~18~H~31~O~5~    UK 7                                  \-                  \-

  **48**   34.7       299.0561   299.0575   C~16~H~11~O~6~    Dimethyl kaemferol                    Flavonoid           0.55 ± 0.03

  **49**   35.2       329.0667   329.0669   C~17~H~13~O~7~    Dimethyl quercetin                    Flavonoid           2.8 ± 0.1
  --------------------------------------------------------------------------------------------------------------------------------------------

NQ: not quantified: compound detected but with a concentration between the detection and quantification limits. UK: unknown compound, compound that was not able to identify.
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Characterization of the vesicles including mean diameter (MD), polydispersity index (PDI), zeta potential (ZP) and entrapment efficiency (EE). Mean values ± standard deviations were obtained from at least 6 replicates.

  Formulation                               MD (nm)    PDI     ZP (mV)   EE (%)
  ----------------------------------------- ---------- ------- --------- ---------
  Empty liposomes                           99 ± 8     0.199   −12 ± 1   
  Empty glycerosomes                        135 ± 3    0.265   −18 ± 2   
  Empty PG-PEVs                             310 ± 4    0.652   −21 ± 1   
  Empty biogelatin-glycerosomes             202 ± 12   0.456   −3 ± 1    
  Empty biogelatin-PG-PEVs                  235 ± 7    0.577   −2 ± 1    
  *L. citriodora* liposomes                 151 ± 13   0.284   −7 ± 1    89 ± 7
  *L. citriodora* glycerosomes              133 ± 9    0.157   −8 ± 2    66 ± 3
  *L. citriodora* PG-PEVs                   109 ± 4    0.191   −7 ± 2    65 ± 4
  *L. citriodora* biogelatin-glycerosomes   149 ± 1    0.117   −8 ± 1    63 ± 8
  *L. citriodora* biogelatin-PG-PEVs        134 ± 5    0.237   −8 ± 1    63 ± 15

PG: propylene glycol.
